Skip to main content
. 2016 Aug 26;9:77. doi: 10.3389/fnmol.2016.00077

Figure 4.

Figure 4

Effects of HC-067047, RN1734, and bicuculline on TRPV4 agonists-induced inhibition of IGABA. (A) In the presence of HC-067047 or RN1734, the inhibition of IGABA by GSK1016790A was decreased from 41.1 ± 4.7% (n = 25) to 3.0 ± 0.6% (n = 10) or to 2.8 ± 0.9% (n = 9), respectively. Unpaired t-test, ∧∧P < 0.01 vs. GSK1016790A. (B) IGABA was markedly inhibited from −22.5±2.2 to −1.9±0.9 pA/pF by the application of bicuculline, and the current was virtually unaffected by GSK1016790A treatment (−1.9±0.4 pA/pF) in the presence of bicuculline. Paired t-test, **P < 0.01 vs. control, n = 7. (C) 4α-PDD-induced inhibition of IGABA was significantly attenuated from 20.0 ± 2.2% (n = 15) to 2.3 ± 0.4% (n = 11) or to 1.7 ± 0.9% (n = 9) by pre-application of HC-067047 or RN1734, respectively. Unpaired t-test, ##P < 0.01 vs. 4α-PDD. (D) In the presence of bicuculline, the current (−1.8±0.7 pA/pF) was virtually unchanged by 4α-PDD treatment (−1.9±0.4 pA/pF). Paired t-test, **P < 0.01 vs. control, n = 7. (E) After pre-application of HC-067047 or RN1734, the inhibition of IGABA by 5,6-EET was reduced from 28.1 ± 4.9% (n = 20) to 3.0 ± 0.9% (n = 10) or to 3.2 ± 0.7% (n = 8), respectively. Unpaired t-test, $$P < 0.01 vs. 5,6-EET. (F) In the presence of bicuculline, the currents were −1.7±0.3 and −1.7±0.8 pA/pF before and during 5,6-EET treatment, respectively. Paired t-test, **P < 0.01 vs. control, n = 7.